Meet the young activists who are challenging the status quo in In The Know: Next Gen
Meet the young activists who are challenging the status quo in In The Know: Next Gen
Today's the last day to shop and save.
The best Cyber Monday smart TV deals for 2020, featuring Samsung, LG, Hisense, Sony & more TV offers
The "US Business Banking and Payments 2020" report has been added to ResearchAndMarkets.com's offering.
Greece’s largest medical association on Monday criticized a decision by the country’s center-right government to impose price caps on coronavirus tests at private labs, warning that the measure could disrupt testing during a spike in infections. The government last week set the price limits at 40 euros ($48) for regular swab tests and 10 euros ($12) for rapid tests, cutting current rates at most labs by more than half. In response, the Panhellenic Medical Association said that the measure would force many independent labs to stop providing COVID-19 tests because they would be too costly for them, putting additional pressure on the state-run health service.
Euro zone governments and the European Central Bank may need to provide more fiscal and monetary support than initially expected because of the effects of the second wave of the COVID-19 pandemic, the International Monetary Fund said on Monday. The overall value of fiscal and monetary support on offer, combined with access to trillions of euros of cheap loans and new EU-level funding still under debate, already exceeds 10 trillion euros. "Risks ... remain clearly to the downside through early 2021 given the ongoing second wave," the IMF said in a regular review of the euro zone economy.
The "Global Linerless Labeling Technology and Market Report 2020" report has been added to ResearchAndMarkets.com's offering.
Stock futures were mostly lower Monday morning as investors gave back some of last week’s gains, which sent the S&P 500 and Nasdaq to fresh record highs and the Dow above 30,000 for the first time ever.
Experts warn of coronavirus surge after widespread Thanksgiving travel * More than 100,000 Covid cases a day over holiday weekend * Moderna Covid vaccine has 94% efficacy, final results confirm * US politics – live coverage * Coronavirus – latest updates
Automotive Interior Material Market Research Report by Type (Fabric, Genuine Leather, Polymer, and Synthetic Leather), by Vehicle (Heavy Commercial Vehicle, Light Commercial Vehicle, and Passenger Vehicle), by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19New York, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Automotive Interior Material Market Research Report by Type, by Vehicle, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05913427/?utm_source=GNW The Global Automotive Interior Material Market is expected to grow from USD 41,235.53 Million in 2019 to USD 55,196.01 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 4.97%.Market Segmentation & Coverage:This research report categorizes the Automotive Interior Material to forecast the revenues and analyze the trends in each of the following sub-markets:Based on Type, the Automotive Interior Material Market studied across Fabric, Genuine Leather, Polymer, and Synthetic Leather. The Synthetic Leather further studied across PU Leather and PVC Leather. Based on Vehicle, the Automotive Interior Material Market studied across Heavy Commercial Vehicle, Light Commercial Vehicle, and Passenger Vehicle. Based on Application, the Automotive Interior Material Market studied across Airbag & Seat Belt, Carpet & Headliner, Dashboard, Door Panel & Trim, and Seat. Based on Geography, the Automotive Interior Material Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Automotive Interior Material Market including Adient PLC, DK Leather Corporation Berhad, Faurecia S.A., Grupo Antolin, Lear Corporation, Sage Automotive Interiors Inc., Seiren Co., Ltd., Toyoda Gosei Co., Ltd., Toyota Boshoku Corporation, and Yanfeng Automotive Interiors. FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Automotive Interior Material Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developmentsThe report answers questions such as:1. What is the market size and forecast of the Global Automotive Interior Material Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Automotive Interior Material Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Automotive Interior Material Market?4. What is the competitive strategic window for opportunities in the Global Automotive Interior Material Market?5. What are the technology trends and regulatory frameworks in the Global Automotive Interior Material Market?6. What are the modes and strategic moves considered suitable for entering the Global Automotive Interior Material Market?Read the full report: https://www.reportlinker.com/p05913427/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
As we sit on the threshold of the final week of the Autumn Nations Cup, it is worth considering what rugby’s embattled administrators were hoping to achieve when they came up with the admirable tournament to fill the gap caused by the pandemic. France, says their head coach Fabien Galthie, will be “unrecognisable” to the team that lit up the Six Nations. It seems a great shame that France picked their first team for the friendly against Wales back in August.
Abu Dhabi's biggest sovereign fund is in talks with U.S. firm KKR to invest in Telecom Italia's (TIM) last-mile network in a deal that has drawn scrutiny from Italy's government, three sources close to the matter told Reuters. The government has special vetting powers to block unwanted bids in industries deemed of strategic importance. TIM agreed in August to sell KKR a 37.5% stake of a newly created company, FiberCop, into which it has transferred its 'last-mile' network connecting street cabinets to people's homes.
The singer admitted attending a ‘small gathering’ for her 30th birthday and said it had been an ‘inexcusable error’.
Sinead Quinn, owner of Quinn Blakey Hairdressing in Oakenshaw, near Bradford, did not appear at Bradford Magistrates’ Court for the hearing.
The actor has said she wasn't aware microphones would pick up everything said in the castle walls.
M1 Kliniken AG / Key word(s): Personnel/MiscellaneousM1 Kliniken AG: Mr. Patrick Brenske joins the board of HAEMATO AG. Promotion of the product business as core task of the integration of the Haemato Group into the M1 Kliniken AG - Group30-Nov-2020 / 15:30 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.M1 Kliniken AG: Mr. Patrick Brenske joins the board of HAEMATO AG. Promotion of the product business as core task of the integration of the Haemato Group into the M1 Kliniken AG - GroupBerlin, 30.11.2020 - M1 Kliniken AG announces that as of today Mr. Patrick Brenske will join the Management Board of HAEMATO AG. At the same time, Mr. Brenske will resign from the Management Board of M1 Kliniken AG, with Dr. Walter von Horstig from now on acting as sole member of the Management Board. Mr. Brenske will continue to advise M1.Before joining M1 Kliniken AG, Mr. Patrick Brenske had already worked for the Haemato Group for about eight years as Head of Purchasing and Sales and led the group from a turnover in the small single-digit million range towards an annual turnover of close to 300 million euros. The attainment of the manufacturing licence in accordance with § 13 AMG (German medicines act) was one of the main drivers of HAEMATO's product business.After the acquisition of almost 50% of HAEMATO AG by M1 Kliniken AG by mid of 2020, M1 Kliniken AG follows the strategy of integrating the value chain and strengthening the product business. This offers potentials for added value - while ensuring quality.About M1 Kliniken AGM1 Kliniken AG is the leading provider of beauty medical health services in Germany. In the aesthetic and surgical field, the group offers products and services of the highest quality standards. Under the brand "M1 Med Beauty", beauty medical treatments are currently offered at more than 35 specialist centres. With six operating theatres and 35 beds, the M1 Schlossklinik für plastische und ästhetische Chirurgie in Berlin is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been driving forward its internationalisation and is currently also active in Austria, Switzerland, the Netherlands, England and Australia. In addition, the Group markets high-quality products under the brands "M1 Select" and "M1 Aesthetics" to private customers as well as doctors, pharmacies and wholesalers.Contact us: M1 Klinken AGGrünauer Strasse 5; D-12557 BerlinT: +49 (0) 30 34 74 74 - 414M: email@example.comW: www.m1-kliniken.de30-Nov-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: M1 Kliniken AG Grünauer Straße 5 12557 Berlin Germany Phone: +49 (0)30 347 47 44 14 Fax: +49 (0)30 347 47 44 17 E-mail: firstname.lastname@example.org Internet: https://www.m1-kliniken.de ISIN: DE000A0STSQ8 WKN: A0STSQ Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1151538 End of Announcement DGAP News Service
Cinedigm (NASDAQ: CIDM) announced today that the Company has added over 1,000 hours of programming to its extensive library. This influx of premium content supports new internal primetime programming strategies to capture a share of the $1.2 billion projected streaming holiday ad spending this season. This move will allow Cinedigm to continue to refresh and curate high quality content across its wide range of streaming networks that reach hundreds of millions of devices.
Downing Strategic Micro-Cap Investment Trust Plc LEI Code: 213800QMYPUW4POFFX69 Net Asset Value The Company announces: Total Assets (including unaudited revenue reserves) at 27 November 2020£39.01m Net Assets (including unaudited revenue reserves) at 27 November 2020£39.01m Number of shares in issue (excluding treasury):53,559,321 The Net Asset Value (NAV) per share at 27 November 2020 was: Per Ordinary share (bid price) - including unaudited current period revenue *72.84p Per Ordinary share (bid price) - excluding current period revenue *72.16p Ordinary share price 60.25p Premium/(Discount) to NAV (including current period revenue)(17.28%) * Current period revenue covers the period 01/03/2020 to 27/11/2020
An extraordinary general meeting of Active Biotech was held on November 30, 2020. The meeting resolved, in accordance with the board’s proposal, on a new share issue with pre-emptive rights for existing shareholders. Through the rights issue, not more than 72,618,240 new shares are issued. Two existing shares entitle to subscription for one new share. The rights issue is covered by free of charge subscription commitments and issue guarantees of approximately SEK 40.0 million. The subscription price amounts to SEK 1.05 per share. The record date for participation in the rights issue is January 4, 2021. Subscription for the new shares shall be made during the period 7 – 21 January 2021. A prospectus regarding the rights issue will be made public prior to the commencement of the subscription period. Preliminary timetable Last day for trading in the Active Biotech share including the right to participate in the rights issue is December 29, 2020, instead of December 30, 2020 as previously communicated. 30 November 2020Extraordinary general meeting29 December 2020Last day for trading in the Active Biotech share including the right to participate in the rights issue.4 January 2021Record date for the right to participate in the rights issue.7 – 21 January 2021Subscription period.7 – 19 January 2021Trading in subscription rights. For more information, please contact: Helén Tuvesson, President and CEOTel. +46 46 19 21 56 Hans Kolam, CFOTel. +46 46 19 20 44 Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a Phase 1/2 clinical program in patients with advanced solid tumors. The small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase 1b/2a for treatment of multiple myeloma. Laquinimod is advancing to phase 2 for treatment of non-infectious uveitis during second half of 2021. Please visit www.activebiotech.com for more information. This information was submitted for publication, through the agency of the contact person set out above, at 15.30 p.m. CET on November 30, 2020. Attachment 201130_PR EGM
Emles Advisors ("Emles"), an asset management firm built to solve the unique challenges of today’s markets, announces the launch of two new exchange-traded funds (ETFs) - the Emles Protective Allocation ETF (DEFN) and the Emles Luxury Goods ETF (LUXE).
Chelverton UK Dividend Trust plc (SDVP) 30-Nov-2020 / 14:29 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. CHELVERTON UK DIVIDEND TRUST PLCINTERIM DIVIDENDIn respect of the financial year ending 30 April 2021, the Company has today declared a second interim dividend in respect of the year 1 May 2020 to 30 April 2021.A second interim dividend of 2.50p (2.40p: 2019) per Ordinary share will be paid on 4 January 2021 to the holders of Ordinary shares on the register at 11 December 2020, with an ex-dividend date of 10 December 2020.Maitland Administration Services Limited - Corporate Secretary30 November 2020 * * * ISIN: GB0006615826, GB00BZ7MQD81 Category Code: DIV TIDM: SDVP LEI Code: 213800DAF47EJ2HT4P78 OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State Sequence No.: 88778 EQS News ID: 1151596 End of Announcement EQS News Service